Tokyo, Japan

Ikuo Nishimoto

USPTO Granted Patents = 10 

Average Co-Inventor Count = 1.8

ph-index = 4

Forward Citations = 127(Granted Patents)


Location History:

  • Kanagawa, JP (2006)
  • Chiba, JP (2011)
  • Tokyo, JP (2003 - 2012)

Company Filing History:


Years Active: 2003-2012

Loading Chart...
10 patents (USPTO):Explore Patents

Title: Ikuo Nishimoto: Innovator in Neurodegenerative Disease Research

Introduction

Ikuo Nishimoto is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of neurodegenerative disease research, holding a total of 10 patents. His work focuses on understanding and developing therapeutic agents for conditions that affect neuronal health.

Latest Patents

Nishimoto's latest patents include innovations related to the Humanin receptor and therapeutic agents for neurodegenerative diseases. One of his notable inventions is directed towards identifying the Humanin receptor or Humanin-like polypeptide receptor (HNR). This invention aims to reveal mechanisms that promote or suppress intracellular signal transduction, which is crucial for neuroprotective activity. Additionally, he has developed a pharmaceutical composition that includes a polypeptide designed to prevent neuronal cell death associated with neurodegenerative diseases.

Career Highlights

Throughout his career, Ikuo Nishimoto has worked with esteemed organizations such as Yamatake Corporation and Keio University. His experience in these institutions has allowed him to advance his research and contribute to the scientific community significantly.

Collaborations

Nishimoto has collaborated with notable colleagues, including Tatsuya Ueno and Masaaki Matsuoka. These partnerships have further enriched his research endeavors and have led to innovative solutions in the field of neurodegenerative diseases.

Conclusion

Ikuo Nishimoto's work exemplifies the intersection of innovation and medical research, particularly in the realm of neurodegenerative diseases. His patents and collaborations highlight his commitment to advancing therapeutic options for these challenging conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…